PolyNovo 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Swami Raote

최고 경영자

AU$1.5m

총 보상

CEO 급여 비율	46.4%
CEO 임기	2.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Swami Raote 의 보수는 PolyNovo 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	AU$2m	AU$707k	AU$5m
Mar 31 2024	n/a	n/a	AU$3m
Dec 31 2023	n/a	n/a	AU$2m
Sep 30 2023	n/a	n/a	-AU$2m
Jun 30 2023	AU$2m	AU$617k	-AU$5m

보상 대 시장: Swami 의 총 보상 ($USD 991.31K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.10M ).

보상과 수익: Swami 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Swami Raote

2.3yrs

테뉴어

AU$1,523,944

보상

Mr. Swami Raote, B. Pharmacy, M.B.A, serves as Director at PolyNovo Limited since September 2022. He serves Entrepreneurs in Residence at DigitalDx Ventures. He serves as Chief Executive Officer at PolyNov...

리더십 팀

이름	위치	테뉴어	보상	소유권
Swami Raote	CEO & Director	2.3yrs	AU$1.52m	데이터 없음
Jan-Marcel Gielen	Chief Financial Officer	5.9yrs	AU$371.95k	0.093% A$ 1.3m
David McQuillan	Chief Technical & Scientific Officer	2.2yrs	AU$538.84k	0.097% A$ 1.4m
Philip Scorgie	Chief Information Officer	1.5yrs	AU$329.02k	데이터 없음
Lior Harel	General Counsel & Company Secretary	less than a year	데이터 없음	데이터 없음
Ingrid Anderson	Chief People Officer	less than a year	데이터 없음	데이터 없음
Edward Graubart	President of North America	5.2yrs	데이터 없음	데이터 없음
Ahmed Hassan	Chief Manufacturing & Supply Chain Officer	less than a year	데이터 없음	데이터 없음
Joseph Amaral	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
David Morris	President of Asia Pacific	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

경험이 풍부한 관리: PNV 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Swami Raote	CEO & Director	2.2yrs	AU$1.52m	데이터 없음
Robyn Elliott	Independent Non-Executive Director	5.1yrs	AU$95.00k	0.011% A$ 152.6k
David Williams	Independent Non-Executive Chairman	10.8yrs	AU$139.43k	3.1% A$ 43.7m
Andrew Lumsden	Independent Non-Executive Director	3.4yrs	AU$95.00k	0.014% A$ 204.0k
Leon Hoare	Independent Non-Executive Director	8.8yrs	AU$95.02k	0.16% A$ 2.2m
Christine Emmanuel-Donnelly	Independent Non-Executive Director	4.5yrs	AU$95.00k	0.039% A$ 552.4k

4.8yrs

평균 재임 기간

경험이 풍부한 이사회: PNV 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

PolyNovo 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Insufficient new directors

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Recent updates

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 20% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: EPS: AU$0.008 (vs AU$0.007 loss in FY 2023)

Now 23% undervalued

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

Now 21% undervalued

Now 20% undervalued

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.002 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Forecast breakeven date pushed back to 2024

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Full year 2022 earnings released: AU$0.002 loss per share (vs AU$0.007 loss in FY 2021)

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

Independent Non-Executive Chairman recently bought AU$434k worth of stock

First half 2022 earnings: EPS in line with expectations, revenues disappoint

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Forecast to breakeven in 2023

PolyNovo Limited Provides an Update on its Hernia Device

Non-Executive Independent Director recently sold AU$571k worth of stock

Independent Non-Executive Chairman recently bought AU$721k worth of stock

PolyNovo Announces It has Received Final Independent Review Board

Revenue beats expectations

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.004 loss in 1H 2020)

New 90-day low: AU$2.42

New 90-day high: AU$3.55

PolyNovo Limited Announces the Breast Device Development Program with Establishment Labs

Non-Executive Independent Director recently sold AU$1.2m worth of stock

PolyNovo Limited Announces US FDA Approves Pivotal Trial IDE

New 90-day high: AU$3.03

New 90-day high: AU$2.74

New 90-day high: AU$2.38

PolyNovo Appoints Innova Medical Oy to Sell Novosorb® BTM in Finland

Independent Non-Executive Chairman recently bought AU$1.0m worth of stock

New 90-day low - AU$2.02

Full year earnings released - AU$0.0063 loss per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간